C4 therapeutics appoints ron cooper as chairman of the board of directors

Cooper brings decades of global pharmaceutical and biotechnology leadership experience bruce downey remains a member of the board of directors and chair of the organization, leadership and compensation committee transition further highlights commitment to strategically transform the board to lead c4t into next phase of growth watertown, mass., june 10, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its board of directors as part of the company's aspiration to become a fully integrated biotechnology company.
CCCC Ratings Summary
CCCC Quant Ranking